Welcome to the OMA Blog

Obesity Pillars Journal Volume 9 A Summary of Included Articles Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes This study investigated the impact of once-weekly semaglutide treatment after laparoscopic sleeve gastrectomy (LSG) in 29 Japanese patients with type 2 diabetes (T2D). Motivational interviewing for weight management among college students during COVID-19: An exploratory randomized controlled trial During the COVID-19 pandemic, obesity rates among U.S. Read Article Patient perceptions of three-dimensional (3D) surface imaging technology and traditional methods used to assess anthropometry The study discusses the limitations of traditional obesity assessment methods, like Body Mass Index (BMI), which fail to accurately reflect individual body composition variations, and highlights the societal and personal challenges faced by individuals in managing their weight, including stigma and reluctance to engage with healthcare services. It introduces three-dimensional (3D) surface imaging as a non-invasive, precise alternative for assessing human body shape and composition, suggesting it could improve engagement with weight management services by providing a more detailed and less stigmatizing assessment. Read Article Effects of phentermine / topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: A randomized, multicenter, double-blind study While anti-obesity medications such as orlistat and glucagon-like peptide (GLP) receptor agonists may reduce blood pressure, the prescribing information for sympathomimetic agents such as phentermine (PHEN) or Phentermine + Topiramate (PHENT/TPM) warn of potential adverse reactions in raising blood pressure. The study focused on the blood pressure-lowering effects of a phentermine and topiramate combination (PHEN/TPM) in overweight and obese patients, comparing its efficacy to placebo and phentermine alone.

Today, there's renewed optimism due to the emergence of GLP1-based drug therapies like Wegovy (semaglutide) and Zepbound (tirzepatide), which demonstrate remarkable effectiveness for weight and health. Unfortunately, many of the available alternatives, like compounded versions of semaglutide and tirzepatide, are not what they are advertised to be. These companies stated that they do not sell the active ingredient to compounding pharmacies, and substances made or distributed by compounding pharmacies or other healthcare practitioners that claim to be semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) have not been reviewed by the FDA for safety, quality, or efficacy. For more information, see the following details: Compounded peptides: An Obesity Medicine Association Position Statement - ScienceDirect | Obesity Medicine Association Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA Compounding and the FDA: Questions and Answers | FDA Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound™ (tirzepatide) | Eli Lilly and Company Responsible Use Letter | Novo Nordisk Things You Should Know About Compounded Anti-Obesity (AOM) Medications | Obesity Medicine Association

The recent results of the SELECT Study published in the New England Journal of Medicine provide invaluable insights into the complex disease of obesity. The report has prompted several of the country’s leading obesity expert organizations, the Obesity Action Coalition (OAC), the Obesity Medicine Association (OMA), The Obesity Society (TOS), the American Society for Metabolic & Bariatric Surgery (ASMBS), and the STOP Obesity Alliance (STOP), to join together in issuing the following statement:

Jennifer Seger, MD, FOMA became a fellow of the OMA in 2016. Read her full interview below to learn more about Dr. Seger and her…

The agenda for Overcoming Obesity 2023 is now available to view! The Overcoming Obesity 2023 conference in San Antonio, TX, Oct 25-29 is the perfect…

Join OMA this October 25-29 in San Antonio, TX for Overcoming Obesity 2023. This conference is the perfect opportunity to network with fellow obesity medicine…

Jerome Puryear, Jr., MD, DABOM, became an OMA member in 2019 and has made a great impact in his time here. He is an active…

Ethan Lazarus, MD, FOMA (Immediate Past-President of the OMA) attended the Annual AMA Meeting as the OMA delegate and Anthony Auriemma, MD, JD (Trustee, OMA…

Initially, Kabir Harricharan Singh, MD became a member to get a discount on attending the Spring 2017 OMA Conference in Seattle, but once he realized…